Trials / Completed
CompletedNCT06336603
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
The Combination Use of Winlevi and Adapalene 0.3% Gel in Real Life Acne Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Winlevi (clascoterone) 1% & Adapalene 0.3% gel | Participants will use Winlevi (clascoterone) 1% twice daily (BID) and Adapalene 0.3% once daily (QD) |
Timeline
- Start date
- 2023-11-15
- Primary completion
- 2024-10-29
- Completion
- 2024-10-29
- First posted
- 2024-03-29
- Last updated
- 2025-10-09
- Results posted
- 2025-10-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06336603. Inclusion in this directory is not an endorsement.